Centivax, Inc.
PrivateLast Round
VC Round
Mar 30, 2026
Total Funding Raised
$79.99M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Centivax, Inc. operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a VC Round in March 2026.
Centivax, Inc. is a biotechnology company that deploys a proprietary computational immune-engineering platform to create universal vaccines and therapies for infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2G
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Centivax, Inc. Comparables
Compare Centivax, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Osivax | 87% | |
| Vivaldi Biosciences, Inc. | 84% | |
| Gylden Pharma Limited | 80% |
For institutional investors. Book with your work email.
Centivax, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 30, 2026 | ||||
| Grant | Jul 8, 2025 | ||||
| Series A | Jul 8, 2025 | ||||
| Seed | Nov 16, 2022 | ||||
| Grant | Nov 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Centivax, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kendall Capital Partners | Series A, VC Round |
| NFX | Series A, Seed |
| Future Ventures | Series A |
| CEPI | Grant |
| NIH RADx | Grant |
| The Bill & Melinda Gates Foundation Trust | Grant |
| Base4 Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 30, 2026
$37M raised in early funding round.
- Mar 30, 2026
Developing a next-generation universal vaccine platform with support from Meiji Seika Pharma.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
Centivax began testing its mRNA-based flu vaccine in humans in Feb '26 in a phase 1 trial enrolling 180 participants, with initial data expected later in 2026.
For institutional investors. Book with your work email.
Centivax, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Centivax, Inc.'s valuation, stock price, and market status.
Is Centivax, Inc. a public or private company?
Centivax, Inc. is a private company.
What is the current stock price of Centivax, Inc.?
Centivax, Inc. is a private company, so its shares have no public market price. Caplight tracks Centivax, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Centivax, Inc. worth (valuation)?
Valuation information for Centivax, Inc. is not publicly available.
Can I buy Centivax, Inc. stock?
Centivax, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Centivax, Inc.'s last funding round?
Centivax, Inc.'s most recent funding round was VC Round on March 30, 2026.
Who are the main investors in Centivax, Inc.?
Key investors in Centivax, Inc. include NFX, Future Ventures, Global Health Investment Corporation, Structure.
Will Centivax, Inc. IPO soon?
No public IPO plans have been announced for Centivax, Inc..
How can I track Centivax, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Centivax, Inc.'s shares on secondary markets.